Quantcast

Industry news that matters to you.  Learn more

Archives for September 2014

NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced the introduction of a new highly multiplexed gene expression panel for the nCounter® Analysis System, the PanCancer Immune Profiling Panel. This novel panel will enable researchers to create profiles of the human immune response in all cancer types, potentially accelerating the discovery and development of drugs, therapies and predictive biomarker signatures for immunotherapy treatment response.

Center for Advanced Cellular Therapeutics to Rise on Penn Medicine Campus

The University of Pennsylvania recently reached an important milestone in its alliance with Novartis as it unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia. The CACT will become the epicenter for research using Chimeric Antigen Receptor technology (CAR), which enables a patient’s T cells to be reprogrammed outside of the body so when they are re-infused into the patient, the T cells have the ability to “hunt” and destroy the cancer cells. Clinical trials using this approach have made headlines around the world.

German Biotech Company sphingotec Expands into the U.S.

sphingotec GmbH recently announced that it has established its U.S. headquarters in Cambridge, Massachusetts. The Germany-based biotechnology company develops tests to detect individual risk factors for cancer, cardiovascular conditions and kidney disease. Its expansion into the U.S. will enable sphingotec to more rapidly meet growing market demand.

Tolero Pharmaceuticals and Eutropics Announce Data Demonstrating Clinical Utility of Praedicare Dx in Guiding New Drug Treatment of CLL Patients

Eutropics, Inc, (Cambridge, MA) and Tolero Pharmaceuticals, Inc, (Lehi, UT) recently announced that clinical study results demonstrating a predictive biomarker for Chronic Lymphocytic Leukemia (CLL) patient response to treatment with Toleros’ experimental drug alvocidib were published in the medical journal Leukemia. The results appear in an article entitled, “Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.” The study, performed in collaboration with Ohio State University and Duke University Medical Centers, compared a novel algorithm readout of Eutropics’ companion diagnostic platform, Praedicare Dx, to positive patient outcome after alvocidib treatment. Importantly, a different algorithm readout of Praedicare Dx was discovered that predicts likelihood of adverse effects, providing further guidance for treatment.

Researchers Report ScreenCell Usage for Colorectal Cancer – CTC Biomarker

In a recent paper, Cancer Biomarkers (Cancer Biomarkers 14 (2014) p.145–150), researchers at Rouen University Hospital, Rome University Hospital-La Sapienza, and University of Medicine and Pharmacy, Cluj-Napoca, Romania report on the use of the ScreenCell Cyto device to capture and characterize Circulating Tumor Cells (CTCs) from patients with colorectal cancer (CRC). This is the first preliminary report on the use of ScreenCell with samples from CRC patients.